lisocabtagene maraleucel
Selected indexed studies
- Lisocabtagene Maraleucel. (, 2006) [PMID:40460228]
- Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. (Blood, 2023) [PMID:36542826]
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. (Lancet, 2020) [PMID:32888407]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. (2020) pubmed
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. (2022) pubmed
- Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. (2024) pubmed
- Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. (2022) pubmed
- Lisocabtagene Maraleucel. (2006) pubmed
- Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. (2023) pubmed
- Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. (2025) pubmed
- Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. (2023) pubmed
- Lisocabtagene Maraleucel for the treatment of B-cell lymphoma. (2021) pubmed
- Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma. (2023) pubmed